Potential resistance mechanisms to dual EGFR targeting in EGFR 20ins
DISEASE PROGRESSION
To explore potential resistance mechanisms to dual EGFR targeting in EGFR 20ins, serial blood samples before treatment, on treatment (C2D1) and at disease progression from 38 patients were obtained for cfDNA analysis. De novo alterations at progression were found in 86.8% (